Dark Matter Blog

JUNE 21, 2023

Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

The Pharma Data

OCTOBER 27, 2020

“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. Heinrich Jehle, managing director of 3a-Diagnostics. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA.

RNA 52

RNA Production International Compliance 52

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. No adverse events were observed and the reactions were similar to those seen in recovered COVID-19 patients, CureVac said ( DID , Nov.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

MARCH 8, 2021

Week 96 findings reinforce the primary (proportion of participants with plasma HIV-1 RNA ?50 50 c/mL at Week 48 (Snapshot, ITT-E)), and secondary endpoints (proportion of participants with plasma HIV-1 RNA ?50 Week 48 primary endpoint (proportion of participants with plasma HIV-1 RNA ?50

RNA 52

RNA Treatment Therapies Licensing 52

LifeSciVC

DECEMBER 5, 2024

combinatorial chemistry, human genetics, functional genomics, mRNA, I/O, CRISPR, RNA editing, and many others). He’s been a leading light in the biotech venture field, investing in essentially every major innovation wave of the last few decades (e.g.,

Marketing 79

Marketing RNA Science Drugs 79

The Pharma Data

MARCH 8, 2021

Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. In addition to the ongoing clinical studies, Merck has conducted a comprehensive nonclinical program to characterize the safety profile of molnupiravir. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

SynBioBeta is one of synthetic biology’s premier events, bringing together a diverse community of thought leaders, technology innovators, engineers, scientists, and policy makers to explore the exciting new advancements that are shaping the future of science. Strateos’ own Daniel Rines, Ph.D.,

Engineering 52

Engineering Protein Expression Research Laboratories RNA 52

The Pharma Data

OCTOBER 14, 2020

Live Webcast : accessible from the Company’s website at www.eloxxpharma.com under Events and Presentations or with this link: [link]. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Eloxx Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

Broad Institute

JULY 11, 2024

IDH1 normally facilitates the activity of enzymes called demethylases, which remove chemical flags called methylation marks from DNA, allowing genes to be transcribed into RNA. In cells with mutant IDH1, this gene is silenced due to the buildup of 2HG, but mIDH1 inhibitors allow demethylases to facilitate cGAS expression.

Treatment 72

Treatment Immune Response Drugs Virus 72

LifeSciVC

JANUARY 16, 2024

Still may be some merit if they are clinical-stage and can achieve once-daily dosing without too steep a cut in efficacy or worsened adverse events vs. peptides, but be wary of the intensely competitive landscape. A permanent gene edit to produce a difficult-to-titrate supply of GLP1 in the liver?

Small Molecule 142

Small Molecule Trials Therapies Disease 142

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. The study is an event-driven trial. Argentina and Brazil.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Vial

DECEMBER 5, 2023

Among others, NGS has led to the identification of disease-causing variants and novel drug targets and an improved understanding of complex biological events, e.g., the heterogeneity of tumors. It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Immune Response Virus RNA 52

DrugBank

JANUARY 29, 2025

Gene therapy strategies targeting oncogene inactivation, such as RNA interference and gene-editing technologies, have shown promise in preclinical and clinical studies. The system comprises a guide RNA that targets a specific DNA locus and the Cas9 enzyme that cleaves the DNA at the target site.

Therapies 52

Therapies DNA RNA Disease 52

The Pharma Data

JANUARY 31, 2021

No serious adverse events related to the vaccine candidates studied were reported. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The candidate vaccines were given in two doses, three weeks apart.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

PLOS: DNA Science

MARCH 28, 2024

One type of histone addition, acetyl groups, bind in patterns that control which genes are expressed (transcribed into RNA and translated into protein) and which genes are hidden, a little like reading only some of the words on a page. Duvyzat reigns in HDAC activity, slowing the cascade of events leading to muscle deterioration.

FDA Approval 96

FDA Approval Treatment FDA DNA 96

The Pharma Data

MAY 31, 2022

Olpasiran is a small interfering RNA designed to lower the body’s production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events.

RNA 52

RNA Treatment Disease Trials 52

PLOS: DNA Science

MARCH 7, 2024

That event blocked synthesis of the protein that signals formation of the tailbone. An Alu repeat is a “retrotransposon,” a short sequence of RNA that is copied into DNA that then inserts into the genome. Retrotransposons increase in number over time as DNA copies are peeled off of RNA templates.

DNA 52

DNA RNA Research Science 52

The Pharma Data

AUGUST 19, 2021

Lenacapavir was generally well-tolerated, with no serious adverse events related to study drug and no study drug discontinuations through the 14-day period, including no discontinuations due to adverse events. The most common adverse events observed were injection site reactions.

Marketing 52

Marketing Treatment FDA FDA Approval 52

Drug Target Review

AUGUST 24, 2023

Infiltration of immune cells into tissues follows a cascade of events, namely rolling, activation, adhesion and transmigration, which are mediated by different molecules. How does GDF-15 impact the tumour microenvironment and the infiltration of T cells into the tumour? in North America) in late 2017.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

Drug Target Review

SEPTEMBER 25, 2024

At TOLREMO, we have developed a proprietary modular phenotypic screening platform that leverages transcriptional reprogramming events associated with non-genetic resistance to deliver new chemical scaffolds and identify novel resistance regulators.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

MARCH 28, 2022

The adverse events (AEs) were mostly mild to moderate in severity and occurred at a similar rate across BIIB078 and placebo groups. We designed BIIB078 to test the prevailing hypothesis that the mechanisms of disease for C9orf72-associated ALS were caused by toxicity associated with the repeat containing RNA and corresponding dipeptides.

RNA 52

RNA Therapies Disease Biosimilars 52

The Pharma Data

JANUARY 17, 2021

The primary endpoint of this trial is to evaluate patients for complete histological clearance of the tumor cells within the treated BCC lesion with secondary endpoints, evaluating subjects for investigational product treatment related adverse events, as well as serious adverse events, and cutaneous skin reactions.

Treatment 52

Treatment Trials FDA Approval RNA 52

The Pharma Data

DECEMBER 17, 2020

All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Ashley R. Source link.

Laboratories 52

Laboratories Pharmaceutical Companies Production RNA 52

Elrig

APRIL 29, 2024

She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

The Pharma Data

MARCH 3, 2022

To replace that, patients must take exogenous insulin by shots or pump and are at risk of dangerous low blood sugar events. The current study extends on that finding and provides crucial mechanistic and clinical insights into the beneficial effects of verapamil in Type 1 diabetes, using proteomics analysis and RNA sequencing.

RNA 52

RNA Treatment Disease Regulations 52

The Pharma Data

OCTOBER 25, 2020

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–( About Moderna. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov.

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

The Pharma Data

MARCH 8, 2021

In both studies, >98% of participants who initiated treatment with Biktarvy and remained in the study achieved and maintained an undetectable viral load (HIV-1 RNA <50 copies/mL) through four years of follow-up (n=235/237 for study 1489, n=241/243 for study 1490). Source link:[link].

Treatment 52

Treatment Therapies RNA Laboratories 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. But now, we’re one step closer. Navin Varadarajan, University of Houston M.D.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

MARCH 5, 2021

This will be adapted to the needs of messenger RNA vaccine production for CureVac’s CVnCoV, the manufacturing of which is highly complex. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic. Download this exclusive report here.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 29, 2021

In a alternate analysis of the BICSTaR study, 97 (n = 149/154) of treatment-naïve grown-ups and 96 (n = 771/800) of treatment-educated grown-ups achieved and maintained virologic repression (HIV-1 RNA< 50 clones/ mL) after one time of treatment. 1 AIDS- defining event at birth). l and/ or ?

Treatment 40

Treatment International RNA Clinical Trials 40

The Pharma Data

JANUARY 12, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Jan. 12, 2021– Moderna, Inc.

Vaccine 52

Vaccine RNA Clinical Trials Science 52

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 16, 2020

A review of solicited adverse events indicated that the vaccine was generally well tolerated. The majority of adverse events were mild or moderate in severity. These solicited adverse events were generally short-lived. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52